GlassScriptPhysician profile
Benjamin Zwain
NPI 1306307103
$1,329.47
in general payments reported to CMS, 2019-2025
18 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.04 · 2022: $460 · 2023: $610 · 2024: $67.05 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.99 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $259.63 | 2022-2025 | Ultomiris |
| Ucb, INC. | $137.54 | 2023 | Briviact, Fintepla |
| Neurelis, INC. | $120.16 | 2022-2023 | Valtoco |
| Abbvie INC. | $109.54 | 2022-2024 | Qulipta, Botox |
| Lundbeck LLC | $98.40 | 2023 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $97.97 | 2022-2024 | Ajovy, Austedo |
| Amgen INC. | $77.75 | 2022 | |
| Sk Life Science, INC. | $59.49 | 2023 | |
| Emd Serono, INC. | $58.95 | 2022-2023 | Mavenclad |
| Octapharma USA, INC. | $51.99 | 2023 | Panzyga |
| Astrazeneca Pharmaceuticals LP | $38.40 | 2022-2023 | |
| Medtronic, INC. | $36.29 | 2024 | Linq II |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.57 | 2023 | Purified Cortrophin Gel |
| Eisai INC. | $21.35 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.56 | 2023 | Nuedexta |
| Pfizer INC. | $20.47 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Zwain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.